SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
Constanze Schneider(Goethe University Frankfurt), Jindřich Činátl(Goethe University Frankfurt)
Cited by 184
Related Papers
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
|Nature Communications|2019|82
Oncolytic Effects of a Novel Influenza A Virus Expressing Interleukin-15 from the NS Reading Frame
|PLoS ONE|2012|44
Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
|Oncology Letters|2017|29
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status
|European Journal of Cancer|2016|0